Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
Estimating the term…
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
An isolated human antibody or antigen-binding fragment thereof that specifically binds human angiopoietin-like protein 3 (hANGPTL3) of SEQ ID NO:161 and neutralizes, reduces, or interferes with, at least one activity of hANGPTL3.
An antibody or antigen-binding fragment thereof which competes for binding to hANGPTL3 with, or which binds the same epitope on hANGPTL3 as, an antibody or antigen-binding fragment comprising a heavy chain and light chain complementarity determining region (CDR) sequence combination selected from the group consisting of 4/6/8/12/14/16, 20/22/24/28/30/32, 36/38/40/44/46/48, 52/54/56/60/62/64, 68/70/72/76/78/80, 84/86/88/92/94/96, 100/102/104/108/110/112, 116/118/120/124/126/128, 132/134/136/140/142/144, 148/150/152/156/158/160 and 182/184/186/190/192/194.
A method of enhancing the clearance of hANGPTL3 from the circulation of a subject in need thereof, the method comprising administering to the subject at least two antibodies or antigen-binding fragments thereof that do not compete with one another for binding to hANGPTL3 and do not block at least one activity of hANGPTL3.
Dependencies are inferred from the claim text.